In a world where everyone’s chasing the next molecule, Biostate AI is chasing time itself, and maybe even beating it.
Founded in June 2023 by David Zhang and Ashwin Gopinath, two minds who don’t just read the science papers, they write them, this startup is making RNA talk louder than it ever has before. Zhang, fresh off co-founding NuProbe and Torus Biosystems, brings 40+ patents and the kind of DNA wizardry that turns biotech blackboards into billion-dollar businesses. Gopinath? He co-founded Palamedrix (acquired by Somalogic), taught at Massachusetts Institute of Technology, and took a personal war, his wife’s fight with leukemia, and turned it into a mission. These aren’t founders. These are forces.
Now Biostate AI just locked in $12M in Series A funding, led by Accel with backup from Gaingels, Mana Ventures, Info Edge Ventures, and a returning lineup of heavy hitters, Matter Venture Partners, Vision Plus Capital , and Catapult Ventures. Toss in angel ammo from Dario Amodei (Anthropic), Michael Schnall-Levin (10x Genomics), and Emily Leproust (Twist Bioscience), and you’ve got an investor roster that reads like a Davos seating chart for the genomic era.
Biostate AI isn’t playing in the margins, they’re building what might become the world’s largest RNA sequencing dataset, targeting oncology, autoimmune disease, and cardiovascular conditions. The playbook? Strip costs by 80% with patented wetlab tech like BIRT and PERD. Scale precision with generativeAI that sees disease before it hits. Make it accessible through subscription-style diagnostics for hospitals and researchers. That’s right, RNA as a service. Science meets Spotify.
Since going commercial two quarters ago, they've processed over 10,000 samples, inked partnerships with 66 institutions, and secured deals to process hundreds of thousands more annually. From MD Anderson Cancer Center to Stanford University School of Medicine to Weill Cornell Medicine, they’re not just knocking on doors, they're rewriting what diagnostics look like inside them.
With headquarters in Houston and labs humming in Palo Alto, Bangalore (Bayosthiti AI), and Shanghai (Baisheng AI), this is a truly global RNA operation. But the strategy stays tight: build FDA-ready models for leukemia and MS, expand U.S. capacity, and license AI insights to pharma and hospitals. If Zhang’s vision to make Biostate the “NVIDIA of bio AI” sounds ambitious, that’s because it is, and because it’s working.
We’re watching a category-definer in motion. Biostate AI isn’t reacting to disease. It’s predicting it. That’s not just biotech, that’s bio-strategy.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.
If engineering peace of mind is what you crave, Vention is your zen.